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education organization whose mission is to help societies address the issues of population aging 
and longevity in positive and constructive ways and to highlight older people’s productivity and
contributions to their families and society as a whole.
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P
e rhaps the greatest fear of old age is
losing one’s mind. Cognitive function
affects a person’s ability to interact
and enjoy life. Loss of the mind may
translate into an inability to even
re c o g n i ze on e’s loved on e s . Fo rt u n a t e ly, t h e
results of recent cl i n i cal work and re s e a rch
insights are increasing our ability to influence
mental health status in aging.
The “l on g ev i ty rev o l u t i on” has increased 
our focus on many aspects of health in aging,
including cognitive health. Cognitive vitality in
old age has become an incre a s i n g ly import a n t
health ca re go a l . Although many older individuals
are enjoying optimal aging, a substantial 
number of them still face their later years with 
serious decrements in cognitive function. These
d e c rements can significa n t ly affect quality 
of life.1 And when cognitive decline progresses
to dementia, the problem becomes far more
s e ri o u s . A l z h e i m e r’s disease (AD), the most
common cause of dementia, has a devastating
impact on individuals and society.
Our focus on achieving cognitive vitality is a
re l a t i ve ly new conceptual appro a ch made
possible by new knowledge gained during the
past decades from research on cognitive aging
and AD. Now, we more clearly understand the
distinctions between normal cognitive aging and
diseases of cognition in old age. Research has 
also resulted in many new preve n t i ve and
t h e rapeutic strategies for AD, and the possibility
of new therapies and life s tyle interve n t i on s
allows us to imagine that cognitive vitality in old
age is an achievable goal. Now, we understand
enough about risk factors for dementia to begin
to design, t e s t , and implement preve n t i ve stra t e g i e s
in cl i n i cal pra c t i c e . This new knowledge makes 
it possible to begin to focus on the prevention
of cognitive decline and the maintenance of
cognitive vitality in older persons.
Ach i eving and maintaining cognitive vitality
with (indeed, despite) aging has been a concern
we have shared for some years.2 Educating the
public about the promotion and protection of
cognitive health is an important goal. It requires
assessment and re d u c t i on of risk factors 
for c o g n i t i ve decl i n e . This focus on cognitive
v i t a l i ty marks an expansion beyond traditional
re c om m e n d a t i ons of health prom o t i on and
disease prevention, as we believe mental and
phys i cal health can be maintained and p rom o t e d .
We want to emph a s i ze that such a pro g ram 
is a life l ong commitment that is based on an
a w a reness of the intera c t i ons of mind and body.
We b e l i eve t h i s w o rk s h o p re p o r t a n d
its publica t i on on the websites of the
I n t e rn a t i onal Lon g ev i ty Center (www. i l c u s a . o r g )
and the Institute for the Study of Aging
(www.aging-institute.org) will serve the public.
Robert N. Butler, M.D.
President and CEO
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Executive Director
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Pa r t i cipant List
M o re people today are living longer lives 
than ever before, and lon g ev i ty is alre a d y
commonplace in both developed and developing
countries. Substantial gains in life expectancy
and in the number and proportion of older
people throughout the world will have a significa n t
impact on our lives and on the pro g rams 
and policies we design for the 21st century.
This longevity revolution represents both an
incredible opportunity and a great challenge.
Without doubt, the most prevalent and tragic
a f f l i c t i on of old age is mental or cognitive
impairment,often resulting in dementia—severe
global cognitive impairment.
Cognitive aging is the term used to describe
changes in memory and other cognitive
functions associated with old age. Most people
e x p e rience changes in memory and other
cognitive functions in old age. In many cases,the
c o g n i t i ve changes associated with normal aging
a re usually mild and do not impair a person’s
a b i l i ty to function on a daily basis. As re s e a rch e r s
in the field of cogniti on , we believe that cognitive
aging is potentially avoidable. Our goal is to find
w ays to maintain cognitive vitality in old age.
Recent studies have begun to classify the diffe re n t
degrees of cognitive impairment associated with
a g i n g.The earliest form of age-associated cognitive
change, characterized by increased forgetfulness,
is ca lled age-associated memory impairm e n t
(AAMI). In this stage, subjective complaints of
m e m o ry loss are accompanied by objective
evidence of impairment. Memory loss associated
with AAMI is generally slight. But it may be
preventable and treatable.
A more serious form of cognitive impairment
with aging is the disorder known as mild cognitive
i mpairment (MCI). MCI is a disorder that can
be identified with psychological tests that use
learning and memory tasks. Individuals with
AAMI do not autom a t i ca lly pro g ress to MCI, b u t
about 15% of individuals diagnosed with MCI do
p ro g ress to Alzheimer’s disease each ye a r.
“ Se n i l i ty ” is the lay term for dementia, a syn d rom e
o f cognitive impairment that affects all aspects 
of thinking, i n cluding abstract re a s on i n g,
j u d g m e n t , l a n g u a g e, m e m o ry, and learn i n g.
According to US studies, about 25% of people
over the age of 75 and about 40% of people over
the age of 80 are affected by dementia.
Alzheimer’s disease is the most common cause
of dementia. As individuals over the age of 85
constitute the most rapidly growing segment 
of our society, cognitive aging and Alzheimer’s
disease represent a significant and increasing
social and econ omic burden to individuals,
families, and society.
Fo rt u n a t e ly, dementia is not an inev i t a b l e
companion of old age. An alternate scenario—
cognitive vitality with aging—is possible. With
this in mind, the Institute for the Study of
E xe c u t ive Summary
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7A g i n g, I n c . , in con j u n c t i on with the Intern a t i on a l
Lon g ev i ty Center—USA, C a nyon Ra n ch
Health Resort , and the Na t i onal Institute 
on Aging, held an interdisciplinary workshop
entitled “Achieving Cognitive Vitality With
Aging” at the Canyon Ranch Health Resort
in Tucson, Arizona on May 2 - 4, 2000. The
workshop brought together expert clinicians
and re s e a rch scientists from diverse back g ro u n d s
and areas of expertise to address the issue of
maintaining cognitive vitality with aging.
THE AIMS OF THE WORKSHOP WERE TO:
• R ev i ew current scientific and cl i n i cal know l e d g e
of normal human cognitive aging, the biologic
m e chanisms that underlie this process, and
risk factors associated with mental decline;
• Make recommendations for lifestyle changes
to maintain cognitive vitality and prevent
mental decline, based on a combination of
current scientific and clinical knowledge; and
• Create a research agenda for the development
of new therapies to prevent mental decline.
The absence of a complete scientific
understanding of the cognitive aging process
presented a genuine challenge to the group.
While new findings are being published and
new technology developed, there remain many
s e c rets about aging. The group strove to identify
risk factors for cognitive aging, such as those
relating to nutri t i on , m e d i cal con d i t i on s ,
psychologic and psychosocial factors, lifestyle,
h o rm on e s , and genetics. Pa rticipants also
explored behaviors that may protect against
c o g n i t i ve decl i n e, i n cluding learning new
things, staying physically active, participating in
l e i s u re activities, p racticing stress re d u c t i on
techniques, seeking help for depression, grief,
or loneliness, eating a nutritionally balanced
d i e t , stopping smok i n g, reducing alcoh o l
c on s u m p t i on , and seeking treatment for
medical problems. The group studied data on
brain plasticity (adaptivity), memory enhancers,
the effects of exe rcise on the brain and
cognition, and interventions to prevent mental
decline in animal models. Potential drugs for
p reventing mental decline and maintaining
c o g n i t i ve vitality, such as acetylcholinesterase
inhibitors, as well as drugs not yet approved for
prevention and treatment of cognitive decline,
were also discussed.
The purpose of this document is to shed light
on the process of cognitive aging and to develop
s t rategies to maintain cognitive vitality.
By doing so, we hope to increase awareness 
of the need for more research on the subject.
In addition, we hope to give physicians, policy
makers, and the general public the tools to
p romote cognitive vitality. Our goal is to
provide information that will ultimately help 
a ll individuals maintain cognitive health
t h roughout the aging process and there b y
s i g n i f i ca n t ly enhance their ove ra ll quality of life .
8By the year 2050, there will be almost 2 billion
people aged 60 years and over in the world. At
that point, the population of older persons will
be larger than that of children (‡14 years of age)
for the first time in recorded human history.3
This process of
global aging is
happening ra p-
i dly. In 1950,
a p p rox i m a t e ly
200 million of
the worl d’s
population was
60 years of age
or older. T h i s
p a rt of the
population has
expanded ra p-
i dly, and the
p rojected future
e x p a n s i o n  
is dramatic
(Figure 1).4
What kind of future can these people look
forward to? What kind of cognitive function
will accompany them into their later years?
Many people approach their later years worried
about memory loss, s h o rtened attention 
span, and incompetence in cognitively complex
situations.5 Some assume that severe cognitive
decline is inevitable. In contrast, others look
forward to the years past age 65 as a vital, active
time in their lives. Many postpone retirement.
Others choose to travel, volunteer, or begin new
careers. To maintain the vitality of their bodies
and minds, many follow anti-aging advice of
u n c e rtain value that they hear about on telev i s i on
or read about in
magazines and
n ew s p a p e r s .
People facing
their later ye a r s
n e e d  s o l i d ,
s c i e n t i f i c
i n f o rm a t i on on 
this  com p l e x
t o p i c — t h e y
d on ’ t  n e e d
m yths or false
h o p e . T h e
I n s t i t u t e f o r
the Study of
A g i n g , t h e
I n t e rn a t i on a l
L o n g e v i t y
C e n t e r, C a nyon Ra n ch Health Resort , and the
Na t i onal Institute on Aging spon s o red this work-
shop to determine what is known and what ques-
t i ons remain to be answered about cognitive vitality
with aging. We hope that our efforts will help
people understand how cognition changes with
n o rmal aging and disease and that this understand-
ing will enable them to make informed decision s
about maintaining their own cognitive health.
T he Workshop Report
Figure 1. Global aging: world population aged 60 and over
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9WHY IS COG N ITI V E VITA LITY IM P O RTA NT?
Having a cl e ar, a c t i ve mind at any age is
important. For older persons, cognitive vitality
may make the difference between dependency
and independent living. Even in less dramatic
cases, cognitive vitality has a tremendous impact
on quality of life.
MA I NT ENA N C E O F COG N ITI V E VITA LITY
HELPS INDIVIDUALS TO …
• Enjoy everyday life fully
• Be productive (either at work, at home,
or through volunteer activities) 
• Acquire new knowledge
• Maintain health 
• Stay involved
• Maintain independent living
• Maintain social and family relationships
• Be creative
• Face challenges
• Avoid depression
Cognitive function is tightly tied to survival.
Studies have shown an association betw e e n
rapid cognitive decline and increased mortality.8
Se p a rating “b o d y ” f u n c t i ons from “m i n d”
f u n c t i ons is impossible, and phys i cal health
appears to be largely intertwined with mental
health and function. After all, the brain is the
control center for the body, and much of what
we do to maintain our health is a function of
“mind over matter.”
THE AGING BRAIN
While we encourage an optimistic approach to
cognitive vitality with aging, we cannot ignore
that the brain does change with age. As it ages,
the rate at which the brain can receive and
p rocess inform a t i on slow s . The re a s ons for 
this are not well understood. Cognition can be
considered a kind of computation process in a
network of billions of brain cells. During aging,
some links in the network break, resulting in
additional time needed to process and react to
information. In most cases, a person is not even
aware of this change because most common
activities do not test the limits of a person’s
ability to process information rapidly. However,
the bottleneck of slowed processing can cause
other shortcomings in cognitive function,9 such
as the memory lapses that are seen in aging.
In addition, complex tasks that require people 
to access multiple memories simultaneously may
be compromised as a person ages.
WHAT IS COGNITION?
Cognition — The process of knowing.
It is a combination of skills, including
k n ow l e d ge acquisition , a t t e n t i on ,
intuition, m e m o ry, l a n g u a g e, p e rc e p t i on ,
skilled motor behaviors, decision making,
goal setting, planning, and judgment.5
C o gn i tive vita l i ty — Good cognitive
f u n c t i on that results from a com p l e x
c om b i n a t i on of re s e rve brain ca p a c i ty,
a c q u i red know l e d g e, and a degree 
of pro t e c t i on against brain insults. Pe o p l e
with high cognitive vitality re m a i n
i n t e ll e c t u a lly sharp as they age.6 , 7
DID YOU KNOW?
The activity of the brain, like the rest 
of the body, generally slows down with
a g i n g. This is ca lled slowed speed 
of processing. Loss of function is the key
factor in aging. Normally, large numbers
of nerve cells are not lost.
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Why does the brain “s l ow dow n”? One suggestion
is that several processes such as those listed
below can result in reduced cognitive vitality.
• Inflammation — In the brain, inflammatory
responses are part of the natural repair process
f o ll owing an injury or infe c t i on . H ow eve r,
chronic, uncontrolled inflammation may tip
the balance toward brain injury rather than
brain repair.10
• O x i d a tive stress — Metabolic pro c e s s e s
produce oxidants (chemicals that damage cells,
m o l e c u l e s , and cellular com p onents such 
as membranes and mitochondria) and anti-
oxidants (chemicals that protect tissues from
oxidants). When long-term oxidant activity
outweighs long-term antioxidant activity, brain 
damage occurs.11
• Ho rmonal Changes — Estrogen acts as a
neurotrophin, which means that it protects
n e u rons from damage and promotes the
p ro d u c t i on of new neurons in the bra i n .1 2
Animal studies show that the postmenopausal
estrogen decline in women may be one of the
factors that accelerate the occurrence of age-
related cognitive impairment.13
• Amyloid deposition — Beta-amyloid (Aß) is
the p ri m a ry protein that com p rises the senile
plaques that form in the brains of Alzheimer’s
disease patients. Deposits of this protein in the
b rain cause brain injury.1 1
IS COGNITIVE DECLINE SOMETHING
EVERYONE SHOULD EXPECT?
Just as the physical effects of inflammation,
oxidative stress, hormonal changes, and amyloid
deposition vary from person to person, cognitive
functioning varies among people and over time.
Mental function generally follows a continuum
(Fi g u re 2) . Some people maintain cognitive
vitality as they age, showing only small losses in
mental function. While some degree of memory
loss can be expected, cognitive or mental decline
in some individuals becomes abnorm a l , b e g i n n i n g
a progression that may ultimately end with
dementia.15 The initial stage of this decline may
be age-associated memory impairment (AAMI).
In this stage, people have subjective complaints
and objective evidence of memory loss.
Diagnosis of AAMI is difficult. The 
next stage in the continuum is mild cognitive
impairment (MCI), which is marked by even
g reater memory loss. Specific psych o l o g i ca l
testing can determine whether the memory loss
f a lls within the normal range or can be
An ti ox i d a n t s — Chemicals such as
vitamins C and E that may prot e c t
n e u rons (nerve cells) by decreasing the
a d verse effects of re a c t i ve oxidants and
m ay promote cognitive vitality.
Neurons — Nerve cells, which commu-
n i cate inform a t i on in the body.
The brain has billions of neurons, which
g i ve it a sizable re s e rve ca p a c i ty to
c ompensate for neurons that are
damaged or destroyed.14
Neurogenesis — The production of new
nerve cells. Recent work indicates that
new brain cells can be made even in
advanced age.
Senile plaques — Deposits of beta-
amyloid in the brain that cause brain
damage associated with the progressive
c o g n i t i ve decline ch a ra c t e ristic of
Alzheimer’s disease.
Alzheimer’s disease — A disease charac-
terized by progressive cognitive decline
caused by brain changes such as 
the degeneration of neurons and the
f o rm a t i on of senile plaques and
neurofibrillary tangles (abnormal debris
inside brain cells).
diagnosed as MCI. MCI may pro g ress to
d e m e n t i a . While AAMI and MCI are
characterized by memory loss alone, dementia
refers to mental decline severe enough to keep 
a person from functioning norm a lly. It is
ch a ra c t e ri zed by memory loss and other
cognitive dysfunction (such as impaired abstract
thinking). Many people fear dementia. It robs
them of their person a l i t i e s , their ability to
interact with others, and their ability to function
independently. Alzheimer’s disease is the most
prevalent cause of dementia in older people.16
Dementia is not a normal part of aging, as it only
affects about 3% to 10% of people over age
65.17,19 Also important to note is that not all
people diagnosed with MCI will end up with
dementia and that long periods may pass before
this con d i t i on deteri o rates into dementia.2 0
While most people over the age of 70 experience
some degree of cognitive decline, particularly
s h o rt - t e rm memory loss, m a ny people age
without any abnormal cognitive decline. Many
centenarians (men more than women) maintain 
high cognitive function. One study showed that
h i g h - f u n c t i oning older adults smoke less,
exercise more, and are more likely to engage in
volunteer activities than lower-functioning older
a d u l t s .2 1 These associations between cert a i n
c o g n i t i ve behaviors and high cognitive function i n g
are not unexpected. As we shall discuss, people
can take behavioral steps to prevent or postpone
mental decline.
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Dementia — A condition marked by
progressive cognitive impairment. This
c on d i t i on , by definition , is seve re
enough to disrupt daily living.17
Mild cognitive impairment — Perhaps a
t ra n s i t i onal stage between age-associated
m e m o ry impairment and dementia,
characterized by noticeable memory loss
but without other changes in cognitive
a b i l i t i e s . Not all people with mild
c o g n i t i ve impairment develop dementia.1 8
Figure 2. Model for phases of brain aging
In this model, s ome degree of cognitive impairment is associated with 
“successful aging.” Against this background, abnormal changes can occur that
progress through age-associated memory impairment (AAMI) and mild cognitive
impairment (MCI) to dementia. At some stage in dementia, irreversible damage
apparently occurs. Adapted from Cotman 2000,10 with permission.
12
WHO IS AT RISK FOR COGNITIVE
DECLINE?
Certain factors make some of us more likely
than others to experience cognitive decl i n e .
People need to be aware that some factors cause
p o t e n t i a lly reversible mental decline and should be
a d d ressed by a phys i c i a n . These include adve r s e
d rug re a c t i on s , ove rm e d i ca t i on , d e p re s s i on ,
metabolic and endocrine (horm onal) disturb a n c e,
t u mors ,t ra u m a ,a l c oh o l i s m , eye and ear pro b l e m s ,
and infe c t i on .2 2 - 2 4 Other risk factors for dementia,
which is not a reversible condition, may be
genetic or env i ron m e n t a l .
25  
These factors should
be con s i d e red in lon g - t e rm preve n t i on stra t e g i e s .
Risk factors vary—some can be changed or
modified, and some cannot. The following table
lists some risks for cognitive decline and/or
dementia and categorizes them.
FACTORS/INTERVENTION S THAT
PROMOTE COGNITIVE FUNCTION
R e s e a rchers are exploring ways to postp on e
and/or treat mild dementia. If successful, these
therapies may have a broader use and help to
keep the mind functioning well as people age.
Also, people may be able to reduce the risk of
cognitive decline and achieve cognitive vitality
by adopting certain preventive strategies that are
discussed below.2
LIFELONG LEARNING AND TRAINING
Animal studies have shown that intellectual
stimulation actually promotes brain growth.46
Studies in people have demonstrated that lower
education levels or low language ability in early
life are associated with cognitive impairment
and dementia in later years.41,47 Education has
been found to protect against cognitive decl i n e
even in those younger than age 65.4 8 I n d e e d , a d u l t
e d u ca t i on and educa t i on a l / i n t e llectual stimu l a t i on
later in life may help to maintain cognitive health.
Fo rt u n a t e ly, the brain maintains its plasticity
( a d a p t i v i ty) even into ve ry old age. In the ve ry old,
repeated training can be effe c t i ve in sustaining
higher levels of cognitive perf o rm a n c e .4 9 Si m p ly
re-testing older subjects during training exe rc i s e s
enhances memory perf o rm a n c e .5 0 Training may
be form a l i zed or it may consist of doing memory
e xe rc i s e s , s u ch as cro s s w o rd puzzles.
Genetic factors
Female gender 26
ApoE4 genotype 27
Medical comorbidities 
Hypertension 28
Heart disease 28
Diabetes 29
E levated low - d e n s i ty lipoprotein ch o l e s t e rol 3 0
High homocysteine levels 31
Transitory ischemic attacks (TIAs) 28
Head trauma 32
Environmental exposure to toxins 
(particularly lead) 33
Lifestyle choices 
Smoking 26,28
Substance abuse, including alcohol and
illicit drugs 34-39
P s y c h o l o g i c a l / p s y c h o s o c i a l
factors 
Low educational achievement 26,40-43
Lack of physical activity 40
La ck of social intera c t i on / l e i s u re activities 4 4
Excessive response to stress 
(excessive cortisol levels) 45
Brain plasticity — The ability of the
brain to change in response to stimuli
(e.g., learning). Despite myths to the
contrary, the brain can rewire itself, even
into old age, and some areas of the brain
may be able to add new cells in response
to stimulation.
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EXERCISE
Lack of physical activity has emerged as a risk
factor for cognitive decline. Encouraging people
to continue engaging in enjoyable phys i ca l
activities as they age is another way of prom o t i n g
co g n i t i ve vitality. Seve ral studies have shown that
e xe rcise has a beneficial effect on the brains of
older person s . Ac t i ve older adults demon s t ra t e
i m p roved blood supply to the bra i n , h i g h e r
c o g n i t i ve test scores in some are a s , and improve d
re a c t i on time. E ven older adults with phys i ca l
and emotional impairment benefit from exe rc i s e
t ra i n i ng. As the Am e ri can work f o rce ages,
e m p l oyers may find it beneficial to encoura g e
a c t i v i ty and provide exe rcise opport u n i t i e s
d u ring the work d ay, as this will help to
i m p rove pro d u c t i v i ty, h e a l t h , and cognitive
f u n c t i on .4 0 , 5 1 - 5 4
DAILY ACTIVITIES
A rich and stimulating work environment may
help maintain cognitive function.This should be
an important consideration for a person thinking
about re t i re m e n t .5 6 Social and nonw o rk activities
a re also correlated with the risk of cognitive
decline in older adults. For this reason, older
people should be encouraged to keep working
and/or to participate in activities like traveling,
k n i t t i n g, g a rd e n i n g, or volunteeri n g. T h ey
should also be encouraged to participate in
group activities that provide opportunities for
social interaction.44
STRESS REDUCTION
Stress reduction techniques have also proved to
be important as part of the daily activities of
older individuals. Animal studies have shown
that chronic stress alters brain structure and can
reduce the body’s ability to maintain normal
physiologic function, which may, in turn, affect
cognitive function.57,58
SLEEP
Older people are often plagued with sleep
problems that can negatively affect cognitive
f u n c t i on . C on t ro lling sleep disturbances and
increasing REM (rapid eye movement or dream)
sleep are associated with preserved cognition and
function.59,60
EMOTIONAL STABILITY
Studies suggest a connection between cognitive
and emotional health. High-functioning older
adults report fewer emotional problems and
score higher on scales of self-efficacy. Older
people who have been married show greater
emotional stability and higher cognitive function
than their peers who never married.61 The stress
of depression in older adults may actually result
in injury to the brain and may be associated with
the increase in the rate of suicide among this
p o p u l a t i on , p a rt i c u l a rly among white men.6 2
Health ca re pro fe s s i onals and patients, t h e re f o re,
need to be alert to the sym p t oms and effects of
d e p re s s i on and make sure it is pro p e rly tre a t e d .2 1 , 6 3
NUTRITION
Nu t ri t i onal interve n t i on has been investigated as a
w ay to delay and/or prevent cognitive impairm e n t .
Some animal studies suggest that reduced caloric
intake may protect against the effects of aging. I n
one study of mice, data showed that a nutri t i o u s
b u t re s t ricted ca l o rie diet, i n t roduced at
weaning, did not reduce adult brain weight but
did reduce adult body size. This study also
demonstrated in animals that caloric restriction
at midl i fe does pro l ong cognitive function ,
although other data do not support this
finding.64 At present, doctors do not generally
promote dieting in older individuals because it
m ay increase fra i l ty or mask disease-re l a t e d
DID YOU KNOW?
Moderate aerobic activity, like walking,
improves function in executive tasks,
such as problem solving, in older people
who previously had not exercised.55
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weight loss. A balanced diet is vital to preserve
general health and vitality.
R e s e a rchers are also looking at the role 
of antioxidants in preserving cognitive vitality
and preventing dementia. Antioxidants act as
s ca ve n g e r s , p rotecting the body against fre e
ra d i cals that can damage brain cell s .6 5 Fre e
ra d i cals are highly re a c t i ve substances that ca u s e
damage through ch e m i cal processes such as
ox i d a t i on . Vi t a m i n s C and E, a l ong with beta
ca ro t e n e, act as antiox i d a n t s . Am ong people aged
6 56 5 and older, those with a higher intake of these
a n t i oxidants have better memory perf o rm a n c e,
suggesting that antioxidants may help preve n t
p ro g re s s i ve cognitive impairm e n t .6 6 C u r re n t ly,
re s e a rch is under way to investigate whether
v i t a m i n E can help prevent or delay Alzheimer’s
disease in older people with MCI.6 7
Though more research is needed in this area,
eating antiox i d a n t - ri ch fruits and ve g e t a b l e s
and/or taking a daily multivitamin may be
b e n e f i c i a l . But like all ch e m i cal substances,
nutrients and other food components can have
negative effects if taken in excess. For example,
the upper limit of intake for vitamin C for adults
over age 50 is 2000 milligrams (mg) a day; more
than this can cause renal dys f u n c t i on and
d i a r rhea and distort the results of some labora t o ry
t es t s . The upper limit re c ommended for
vitamin E is 1000 mg a day.68
The Institute of Medicine’s Food and Nutrition
B o a rd re c e n t ly released the newest dietary re fe rence
intake values, which gives suggested daily doses
and tolerable upper limits for vitamins C and E.
The report does not recommend a daily or upper
intake level for carotenoids such as beta ca ro t e n e,
so people should be ca reful not to take them in
high doses. The re p o rt re c ommends taking beta
ca rotene supplements on ly for the preve n t i on and
c on t rol of vitamin A deficiency.6 8
THE EFFECT OF MEDICAL PROBLEMS/
INTERVENTION S ON COGNITION
As people age they often need to cope with
medical conditions that may affect cognition.
The effects of some conditions, like stroke, may
be obvious, while other changes, like hormone
levels that are reduced in aging, may affect 
cognition in more subtle ways.
INJURIES
Brain injuries occur most frequently in two age
groups: people aged 15 to 24 years and people
aged 75 and older. Brain injury can result in
lifelong impairment of physical, cognitive, and
psychosocial functioning. Many brain injuries
a re not tre a t a b l e, so preve n t i on thro u g h
precautionary measures such as wearing seat
b e l t s , bike helmets, and re f l e c t i ve cl o t h i n g
should be the main focus.69 In addition, research
has shown that professional soccer players who
frequently “head” the ball often suffer from brain
injury. With the growing number of children
participating in youth soccer programs, parents,
children, and coaches should be educated about
the potential negative effects of this technique,
and it should be discouraged by parents and
coaches alike.70 Boxing is another sporting activ-
ity associated with a risk of brain injury and
dementia. In general, people who participate in
athletic activities should take caution to ensure
that the head is protected.
ALCOHOL AND SMOKING
Some studies have suggested that nicotine may
improve information processing and memory.71
Current research is investigating new drugs that
mimic the effect of nicotine on cognitive
f u n c t i on .7 2 H ow eve r, c i g a rette smoking has
n u m e rous lon g - t e rm adverse effects on the
heart, lungs, and brain, and a number of studies
show negative effects of smoking on cognition.73
Excessive alcohol consumption can cause nerve
cell death, which may contribute to dementia
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and is associated with rapid cognitive decline in
A l z h e i m e r’s disease patients.7 4 R e s e a rch on
people who have Alzheimer’s disease, however,
excludes people with known heavy alcohol use,
leaving many questions about the association of
alcohol and Alzheimer’s disease unanswered.75
M o d e rate alcohol con s u m p t i on may help
p revent cognitive decl i n e, p o s s i b ly thro u g h
effects on the cerebral blood vessels.76 But the
evidence is not conclusive, and recommending
that older individuals use alcohol for medicinal
purposes is risky, since alcoholism is a significant
problem in this age group.77
HORMONAL AND DRUG SUPPLEMENTS
Alzheimer’s disease is more common in women
than in men, and researchers have found a
relationship between estrogen deficiency and
Alzheimer’s disease. Estrogen may play a role in
maintaining neuronal health and some aspects of
cognitive function in older women.78 Findings
suggest that estrogen replacement thera p y
enhances new learning and helps maintain
verbal memory. Results from animal and human
studies of estrogen replacement therapy 
a re prom i s i n g, but the findings are not
conclusive.12,17,79 Further research is needed to
d e t e rmine whether estrogen replacement thera p y
can protect women from cognitive decl i n e .
Those considering hormone supplements may
wish to consider the potential benefit for
p reventing cognitive decline when assessing 
the risks and benefits of these therapies. Studies 
a re also on going to evaluate the effect of
testosterone on cognitive function with aging.
Dehydroepiandrosterone (DHEA), a natural
p recursor of estrogen and testosteron e, has been
a d ve rtised as a supplement to boost memory and as
a cure for many ills of aging.Though DHEA leve l s
do decline as people age, re s e a rch does not support
these health cl a i m s .8 0 Until further re s e a rch is
ca r ried out, DHEA is not re c ommended for the
p reve n t i on of cognitive decline or for enhancement
of cognitive function in older people.
Melatonin, a hormone produced by the pineal
gland in the brain, is a highly advertised over-
the-counter substance purported to improve the
q u a l i ty of sleep. Some studies show that
melatonin levels fall with age, but others do not.
Some scientists think that lower melatonin levels
may be associated with sleep disorders in some
older people, which may in turn cause cognitive
i m p a i rm e n t . H ow eve r, until well - c on t ro ll e d
clinical trials are conducted, melatonin is not
recommended as a long-term supplement.19
Human growth hormone levels also decline as
we age.81 Half of all people age 70 and older have
s ome deficiency of this horm on e . St u d i e s
investigating whether human growth hormone
can improve cognitive functioning have had
m i xed re s u l t s . M o re studies are needed before
treatment with this horm one can be re c om m e n d e d
f or maintaining cog n i t i ve vitality,1 9 e s p e c i a lly since
the lon g - t e rm adverse effects of this treatment 
a re u n k n ow n .
HYPERTENSION, DIABETES, AND
VASCULAR DISEASE
Multiple chronic diseases have been associated
with memory impairment. Hypertension (high
blood pressure) and heart disease affect almost
one third of today’s older population .1 9
H yp e rt e n s i on and other forms of vascular
disease may con t ribute heavily to vascular 
( mu l t i - i n f a rct) dementia, the second most
common form of age-related dementia, which
accounts for approximately 15% of all late-life
dementias.23 Blood pressure control is important
to a person’s ove ra ll health, and effe c t i ve
treatment of hypertension is likely to prevent
cognitive decline by reducing the risk of stroke.82
M o re re s e a rch is needed to definitive ly
determine whether treatment of hypertension
p revents cognitive decl i n e . C on d i t i ons associated
with heart disease, such as atrial fibrillation,
m yo ca rdial infarc t i on , and con g e s t i ve heart failure,
have been linked to cognitive decline.83,84
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D a i ly low-dose aspirin therapy is oft e n
recommended for people at risk for heart attack
and strok e . Some re s e a rch has shown that
aspirin is moderately beneficial in preventing
cognitive decline.85 Other studies do not show a
difference between aspirin users and nonusers.86
Atherosclerosis is also a risk factor for dementia
and has been shown to be associated with poor
cognitive function. 87 Therefore, eating a low-fat
diet and, if necessary, taking ch o l e s t e ro l - l ow e ri n g
medication to control this condition may protect
against cognitive decl i n e . M o re re s e a rch is needed
to assess whether treatment of atherosclerosis
will improve cognitive functioning.
Diabetes, a common condition in older people,
is a significant cause of sickness and death.
Older people with diabetes may have impaired
cognitive function.29 However, the issue of the
re l a t i onship between cognition and elev a t e d
glucose (blood sugar) levels in diabetes is difficult
to interpret, since the brain needs glucose for
cognition.88 Glucose, which is the body’s main
source of energy and is produced from digested
food, such as starch, cane sugar, maltose, and
l a c t o s e, has been shown to be effe c t i ve in
enhancing cognitive perf o rmance in healthy
young and older adults as well as in individuals
with Alzheimer’s disease.8 9 R e s e a rch suggests
that cognition may be impaired in hypoglycemia
(low blood sugar) and in hyperglycemia (high
blood sugar), both complications of diabetes.90
I n d e e d , poor metabolic con t rol (sustained
hyperglycemia) in people with diabetes has been
linked to reduced cognitive functioning.91 Given
this re l a t i on s h i p, studies of new drugs for tre a t i n g
d iabetes should include cognitive function as an
endpoint, especially if these drugs are likely to
cause hypoglycemia. Furthermore, diabetes and
poor con t rol of blood glucose levels have been
s h own to con t ribute to ca rd i ovascular disease and
s t rok e, w h i ch are also risk factors for impaire d
c o g n i t i ve function i n g.9 2 People with diabetes
should avoid both hyp e r g lycemia and hyp o-
g lycemia in order to pre s e rve cognitive function .
Vascular dementi a —– A con d i t i on
caused by multiple mini-strokes that
result in brain damage and loss of
cognitive function. It is the second most
common type of dementia. Risk factors
for this condition include myocardial
infarction (heart attack), hypertension
(high blood pressure), atherosclerosis,
diabetes mellitus, obesity, a sedentary
lifestyle, and smoking.
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*These are the only types of drugs approved by the Food and Drug Administration for treatment of Alzheimer’s disease. 
†Cyclic response-element binding protein.      ‡Dehydroepiandrosterone.       §Nonsteroidal anti-inflammatory drugs.
SU M M A RY O F RE CO M M EN D ED AP P ROAC H ES TO MA I NTA I N I N G COG N ITI V E VITA LITY
The varied approaches to achieving and maintaining cognitive vitality that have been discussed are
summarized in practical terms in the following table.
BEHAVIORS THAT MAY PROTECT AGAINST COGNITIVE DECLINE
• Keep challenging yourself to learn new things (“Use it or lose it”) 
• Stay physically active (“Move it or lose it” may be truer than we realize!) 
• Remain socially active
• Participate in leisure activities. Practice daily stress-reduction techniques, such as meditation and/or
yoga. Get a restful night ’s sleep when possible 
• Seek out the help you need if you suffer from depression, grief, or loneliness 
• Eat well, but not too much; keep calorie intake moderate. Eat antioxidant-rich fruits and vegetables 
• Take a daily multivitamin/mineral supplement but avoid taking excessive amounts 
• Be safe and avoid head trauma—fasten seat belts, use a bike helmet and other safety gear, and avoid
“heading”. Boxing is strongly associated with a risk of brain injury and dementia 
• If you smoke, stop!
• If you drink, use alcohol in moderation—less is probably better. Do not take dehydroepiandrosterone
(DHEA), human growth hormone, melatonin, or other over-the-counter anti-aging supplements 
without consulting your physician  
• Make sure you receive proper treatment if you have high blood pressure, high cholesterol, or other
cardiovascular conditions  
• Make sure to keep diabetes, heart disease, and other medical conditions under control
• Use sensory aids (hearing aids, reading glasses, etc.) to maximize interaction with the environment  
• If you are a woman, consider estrogen replacement therapy carefully and discuss it with your doctor 
PATHOLOGIC CHANGES LEADING TO COGNITIVE DYSFUNCTION AND
POSSIBLE THERAPEUTIC INTERVENTIONS
Pathologic Change Therapeutic Intervention
Cognitive Enhancers
Reduced neurotransmitter production/function Acetylcholinesterase inhibitors*93-98
(fewer or weaker signals between nerves)
Nicotinic agonists99
Glutamate modulators93,100-102 
Muscarinic (M1) agonists103
Muscarinic (M2) antagonists103
Huperzine A104
Gingko biloba105
CREB† enhancers106-108
Disease Modifying Agents
Fo rm a t i on of senile plaques Amyloid vaccine109
Inhibitors of synthesis and production of 
beta-amyloid precursor110
Beta and gamma secretase inhibitors110 
Alpha secretase enhancers
Inhibitors of amyloid fibrillogenesis and aggregration
Ne u ral dys f u n c t i on / c e ll death Glutamate antagonists
Ne u ro t ro phins (NGF, B D N F, A IT-0 8 2 )1 1 1 - 1 1 4
Caspase inhibitors
Glucocorticoid antagonists 
Decreased hormonal function Estrogen replacement17,115-122
Testosterone replacement123,124
Other horm on e s :D H E A‡, m e l a t on i n1 9 , 8 1 , 1 2 5 , 1 2 6
Inflammation Anti-inflammatory agents (e.g., NSAIDs§)127,128
Oxidative stress/free radical production Antioxidants (e.g., vitamin E,vitamin C)129,130 
Elevated homocysteine levels Nutritional supplements 
(vitamin B6, vitamin B12, and folate)
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THE FUTURE OF DRUG THERAPY TO
MAINTAIN COGNITIVE VITALITY
T h ree medica t i ons (all acetyl ch o l i n e s t e ra s e
inhibitors) are available and several are currently
under deve l o pment for the t reatment of cognitive
di s o rders and Alzheimer’s disease. T h e s e
m e d i ca t i ons fall into seve ral ca t e go ries based on
w h i ch part of the Alzheimer’s disease pro c e s s
t h ey target.
Most of these types of medications are being
examined for treatment of dementia, but some
are under study for earlier stages of cognitive
decline, particularly the MCI stage.120 But what
about drugs to improve cognition in people who
do not have MCI or Alzheimer’s disease but are
p ri m a ri ly suffe ring from “n o rmal cognitive
aging”? Disease-modifying agents may be useful
to prevent Alzheimer’s disease and cognitive
decline with aging, but much research needs to
be done.
Some interest is growing in this area of cognitive
e n h a n c e m e n t .5 An example of a cognitive
enhancer is cyclic AMP re s p on s e - e l e m e n t
binding protein (CREB ) . With cognitive
training this protein is produced in the brain.
Its expression has been linked to long-term
m e m o ry form a t i on in animals.1 0 6 E ve n t u a lly,
scientists may be able to develop methods of
enhancing brain levels of pro t e i n s , s u ch as
CREB, that might reduce the amount of time
and effort needed to commit things to long-term
memory. However, the ethics of using cognitive
e n h a n c e r s , s u ch as Ritalin®, in the genera l
population is an issue of debate because their
long-term effects are unknown. Double-blind,
placebo-controlled trials to test the effects of
drugs on cognitive decline and dementia are
necessary before drugs can be prescribed to treat
these conditions.
FUTURE DIRECTIONS FOR
COGNITIVE HEALTH
Our rapidly aging population requires us, as a
society, to make fundamental changes in policy
and research to ensure that older adults maintain
the level of cognitive vitality needed to lead
productive, satisfying lives.
Health ca re pra c t i t i oners can con t ribute to the pro-
m o t i on of cognitive vitality in the foll owing ways :
• Make cognitive vitality an important goal.
Practitioners should talk with patients about
how different conditions or treatments affect
their minds. Some patients may become
motivated to change their behavior (such as
s m oking) or to take medica t i ons to improve other
c on d i t ions (such as diabetes or hypertension), if
they think those interventions will keep their
cognitive faculties intact.
• Do not assume that the cognitively impaired
patient cannot be tre a t e d .A ll individuals re p o rt-
ing cognitive changes with aging should be ev a l-
u a t e d . Pra c t i t i oners should look first for causes of
p o t e n t i a lly reversible impairment and treat them.
If there are non e, patients should be re fe r red for
a diagnostic exam. R e l a t i ves of dementia patients
should be directed to the Alzheimer’s Disease
E d u ca t i on and Refe r ral Center (ADEAR) and
the Alzheimer’s Association for inform a t i on and
s u p p o rt serv i c e s .
• Make sure patients do not have unrecognized
or untreated sensory impairments that
c on t ribute to their pro b l e m s . Pra c t i t i on e r s
should also use technologies that help those
with sensory impairment to interact with their
environment (e.g., hearing aids).131
So c i e ty at large can promote educa t i on a l
endeavors and implement policy changes to help
its members achieve and maintain cognitive
vitality. Some of these changes can be instituted
by community organizations; others require the
government to change its policies and promote
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new types of funding. Specific interventions
include the following:
• Lo cal com munities should institute “g e t - u p - o f f -
yo u r - a p a t hy ” agendas to encourage people to get
m oving intell e c t u a lly, phys i ca lly, and socially as a
means of promoting cognitive vitality.
• The gove rnment s h o u l d s u p p o rt the deve l o p-
ment of a national population database that
studies people longitudinally (over time) to
assess cognitive function .1 Diagnosis of
patients for inclusion in such a study should be
covered under diagnostic-related group (DRG)
codes. A concerted effort should be made to
include cognitive outcome measures in health-
related longitudinal studies (e.g., longitudinal
cardiovascular studies).
• The NIA should continue to develop interdis-
ciplinary consortia to encourage researchers
with diffe rent areas of expertise to com e
together to address the re s e a rch issues related 
to ach i eving and maintaining cognitive
v i t a l i ty,1 , 1 3 2 in addition to, but separate from , t h e
considerable amount of funding curre n t ly
d i rected to Alzheimer’s disease. Su ch con c e rt e d
re search efforts should continue to be used 
for studies such as the NIA Baltimore
Longitudinal Study of Aging.
R e s e a rchers also need to target specific objective s
to advance knowledge about cognitive vitality.T h e
f o ll owing will facilitate the study of certain issues:
• Better descri p t i on of the specific phys i ca l
changes that occur in the brain with normal
aging and those that occur in older people with
M C I . These changes should be examined 
on the molecular, cellular, organ system, and
individual level.
• Genetic studies. The role of genetic factors
requires further study.
• Sensitive biologic markers of normal cognitive
decline.1 Measures of patient behavior are o ft e n
not sensitive enough to tra ck changes over time,
p a rt i c u l a rly with cognitive thera p i e s . Biologic
markers that can be used in this way need to be
developed.
• Additional postmortem studies. Psychological
tests conducted over the course of normal
aging should be paired with autopsy results 
so that the functional changes can be linked to
anatomic changes.132
• Animal studies. Better animal models of norm a l
cognitive aging need to be developed. A rapid
test for cognitive impairment in the rat should
be developed. Aging models and testing should
be standardized across laboratories doing cog-
nition research. Improved imaging systems are
needed so that small animal brains can be
examined.
• Examination of the effects that social and 
cultural conditions (i.e., education, early life
experiences, sense of con t rol or wort h , etc.) have
on cognitive vitality later in life.
• Double-blind, placebo-controlled clinical trials
to assess the effects of putative agents on
cognitive decline and dementia.
CONCLUSIONS
Cognitive vitality is critical to optimal aging.
Although many questions about the aging brain
re m a i n , we now have suggestions for preve n t i ve
s t rategies and interve n t i ons that promote cognitive
v i t al i ty. With these in mind, people can take 
c on c rete steps to maintain their intellectual vigo r.
Physicians and other health care providers can
play a major role in assisting individuals to
achieve and maintain c o g n i t i ve vitality. As our
k n owledge base incre a s e s , t h e o p t i ons for
p romoting cognitive health are also likely to
expand to meet the demands of a grow i n g
number of people who will want to re m a i n
c o g n i t i ve ly vital in their later ye a r s .
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